Post-ischemic treatment with candesartan protects from cerebral ischemic/reperfusion injury in normotensive rat

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 4, 2012, Pages 286-289

  Panahpour, Hamdollah ^a   Nouri, Mohammad ^a  

^a ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AT1 receptor; Candesartan; Focal cerebral ischemia; RAS; Rat

Indexed keywords

CANDESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MOTOR PERFORMANCE; NONHUMAN; RAT; RECEPTOR BLOCKING;

EID: 84870736494     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends in neurosciences 1999;22(9):391-397.
2. Ferrari R CA, Curello S, Ceconi C, Boraso A, Visioli O. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol 1992;20:694-704.
3. Kohara K MH, Okuda N, Higaki J, Ogihara T. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993;21:975-979.
4. Thone-Reineke C ZM, Neumann C, Krikov M, Li J, Gerova N, Unger T. Are angiotensin receptor blockers neuroprotective? Curr Hypertens Rep 2004;6:257-266.
5. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT (1)-receptor blockers. Journal of human hypertension 2002;16:S64-S70.
6. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G. The Angiotensin II Type 1-Receptor Blocker Candesartan Increases Cerebral Blood Flow, Reduces Infarct Size, and Improves Neurologic Outcome After Transient Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow & Metabolism 2004;24(4):467-474.
7. Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002;33(9):2297-2303.
8. Hungerhuber E, Zausinger S, Westermaier T, Plesnila N, Schmid-Elsaesser R. Simultaneous bilateral laser Doppler fluxmetry and electrophysiological recording during middle cerebral artery occlusion in rats. Journal of neuroscience methods 2006;154(1):109-115.
9. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD, Hsu CY. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke 1996;27(9):1616-1623.
10. Panahpour H, Dehghani G. Inhibition of central angiotensinconverting enzyme with enalapril protects the brain from ischemia/reperfusion injury in normotensive rat. DARU Journal of Pharmaceutical Sciences 2010;18(1):35-40.
11. Panahpour H, Nekouian A, Dehghan GA. Inhibition of angiotensin-converting enzyme reduces cerebral infarction size in experimental-induced focal cerebral ischemia in the rat. IJMS 2007;32(1):12-17.
12. Jain A, Chaturvedi S.C, Sharma R. Structural insight for benzimidazole as angiotensin II AT1 receptor antagonist by using molecular property and biological activity correlation: Qsar approach. Int J Pharm PharmSci. 2011;3(Suppl 5):541-546.
13. Brdon J KS, Hagemann F, Zhao Y, Culman J, Gohlke P. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens Suppl 2007;25:187-196.
14. Omura-Matsuoka E, Yagita Y, Sasaki T, Oyama N, Sugiyama Y, Okasaki S, Sakoda S. Postischemic adminstration of angiotensin II type 1 receptor blocker reduces cerebral infaction size in hypertensive rats. Hypertens Res 2009;7:548-553.
15. Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose - response study. J Pharmacol Exp Ther 2008;326(3):773-782.
16. Fu H, Pelisch N, Nakano D, Liu G, Uneo M, Miki T, Masugata H, Sueda Y, Itano T, Matsumoto M, Nishiyama A, Kohno M. Therapeutic effects of postischemic treatment with hypotensive doses of an agiotensin II receptor blocker on transient focal cerebral ischemia. J Hypertens Suppl 2011;29(11):2210-2219.
17. Saavedra JM, Ito T, Nishimura Y. The role of angiotensin II AT1-receptors in the regulation of the cerebral blood flow and brain ischaemia. J Renin Angiotensin Aldosterone Syst 2001;2:S102-S109.
18. Vraamark T, Waldemar G, Strandgaard S, Paulson OB. Angiotensin receptor antagonist CV-11974 and cerebral blood flow autoregulation. J Hypertens Suppl 1995;13:755-761.
19. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000;31(2478-2486).
20. Nishimura Y, Xu T, Johren O, Hauser W, Saavedra JM. The angiotensin AT1 receptor antagonist candesartan regulates cerebral blood flow and brain angiotensin AT1 receptor expression. Basic Res Cardiol 1998;93:63-68.
21. Blume A, Herdegen T, Unger T. Angiotensin peptides and inducible transcription factors. J Mol Med 1999;77:339-357.
22. Walther T, Olah L, Harms C, Maul B, Bader M, Hortnagl H, Schultheiss HP, Mies G. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002;16:169-176.
23. Jayesh K.B, Sabin T, Nanjan MJ. Effect of oral supplementation of vitamin C on glycemic control and lipid profile in patients with type 2 diabetes mellitus. Int J Pharm PharmSci. 2012;4(2):524-527.
24. Sugawara T, Kinouchi H, Oda M, Shoji H, Omae T, Mizoi K. Candesartan reduces superoxide production after global cerebral ischemia. Neuroreport 2005;16:325-328.
25. Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. American Journal of Physiology-Cell Physiology 1998;274(1):C214-C220.